Comparing the current results to its competitors, Twist Bioscience reported Revenue increase in the 2 quarter 2026 by 19.31 % year on year. The sales growth was above Twist Bioscience's competitors' average revenue growth of 4.99 %, achieved in the same quarter.
Twist Bioscience Corporation, slower than the average decrease reported by the company's competitors of -1.56 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -1.56 %
Overall company sales advanced by 19.31 % Twist Bioscience outperformed its competitors in this segment and improved market share, to approx. 0.5 %. << More on TWST Market Share.
*Market share is calculated based on total revenue.
September 9, 2024
Embracing Sustainability in Biotechnology: Twist Bioscience s Commitment to Corporate ResponsibilityIn a landscape increasingly dominated by environmental concerns and the quest for sustainability, Twist Bioscience Corporation (NASDAQ: TWST) has made significant strides with the release of its 2024 Corporate Responsibility Report. This document sheds light on the company s commitment to ethical practices, sustainability initiatives, and social responsibility cornerstones in the modern biotech industry.Twist Bioscience, known for its innovative approach to synthetic DNA production via a cutting-edge silicon platform, has taken a definitive stand by quantifying the carbon footprint of its oligo manufacturing ...
July 10, 2024
Twist Bioscience Corporation, a leading provider of high-quality synthetic DNA using its innovative silicon platform, has recently expanded its high-throughput antibody portfolio. The company announced the launch of a CHO (Chinese hamster ovary) cell line for its Twist Express Antibodies, complementing its existing HEK293 expression system. This development aims to address the increasing demand for biotherapeutic drugs manufactured using CHO cell lines, which have become the preferred choice in the biopharmaceutical industry.CHO Cell Lines as a Preferred Platform for Biotherapeutic Manufacturing:In the field of biopharmaceutical manufacturing, CHO cell lines have gained immense popularity due to their abilit...
May 13, 2024
Twist Bioscience Revolutionizes High-throughput Screening with the Launch of Multiplexed Gene FragmentsIn the field of pharmaceutical sciences, high-throughput screening (HTS) plays a crucial role in accelerating drug discovery and development processes. With the ever-increasing demand for novel therapies and advancements in genomics, there is a need for innovative technologies that can streamline the screening of large DNA libraries. In response to this, Twist Bioscience Corporation, a prominent player in the synthetic DNA industry, has announced the launch of its new product, Twist Multiplexed Gene Fragments (MGFs). This article aims to provide an extensive overview of the potential impact of this groundbr...
February 6, 2024
In a groundbreaking collaboration, Twist Bioscience Corporation and Element Biosciences have joined forces to revolutionize exome sequencing and empower scientific advancements. Twist Bioscience, renowned for its state-of-the-art silicon platform that enables the synthesis of high-quality synthetic DNA, will be partnering with Element Biosciences, a leading developer of pioneering technologies. Together, they aim to develop the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow specifically designed for Element s AVITI System, a breakthrough in genetic sequencing.The partnership between Twist Bioscience and Element Biosciences marks a significant milestone in the field of genomic researc...
February 5, 2024
Twist Bioscience Corporation (NASDAQ: TWST), an industry trailblazer renowned for their success in offering high-quality synthetic DNA via a silicon platform, has officially announced early access to their groundbreaking Twist Flex Prep Ultra High-Throughput (UHT) Kit. Designed to enable unparalleled throughput at a significantly reduced cost compared to existing market solutions, this state-of-the-art technology is set to secure the pace of Next-Generation-Sequencing (NGS) microarray conversion.Located in South San Francisco, California, Twist Bioscience s introduction of the Twist Flex Prep UHT Kit demonstrates the firm’s commitment to lead, innovate, and disrupt market norms. By replacing traditional me...
In an era where advancements in genetic research are transforming healthcare and enabling groundbreaking innovations, Twist Bioscience Corporation has emerged as a frontrunner. The California-based company has once again disrupted the scientific community with its latest product release, the Twist Full Length Unique Dual Index Adapters. These adapters not only facilitate PCR-free whole genome sequencing (WGS) but also enable highly efficient multiplexing on a large scale. This development marks a significant milestone in the field of genetic sequencing, opening up new possibilities for researchers and clinicians alike. Enhancing Whole Genome Sequencing: Traditional PCR-based methods often i...
Publicly Traded Peers of Twist Bioscience Corporation
Crispr Therapeutics Ag Share Performance
+1.06%
This Quarter
Crispr Therapeutics Ag
Profile
CRISPR Therapeutics AG is a biopharmaceutical company focused on developing transformative gene-based medicines using its CRISPR/Cas9 gene-editing platform. They aim to leverage the potential of CRISPR to treat severe genetic diseases by directly modifying genes within the body's cells. The company collaborates with partners, conducts research and development of their therapeutics, and ultimately aims to bring their innovative treatments to market.
Illumina Inc is a leading company in the genomics sector, focusing on next-generation sequencing technologies that enhance genetic analysis. Their business model encompasses a diverse range of products, including sequencing platforms, reagents, and bioinformatics solutions, which together facilitate comprehensive genomic studies for researchers. By integrating these tools, Illumina supports advancements in fields such as oncology, drug discovery, and personalized healthcare, positioning itself at the forefront of genomic innovation.
Omniab Inc is a technology company that operates on a B2B (business-to-business) model, offering a range of software solutions and services. The company focuses on providing customized software applications to help businesses streamline their operations, enhance productivity, and improve efficiency. Omniab Inc also offers consultation services to assist companies in optimizing their IT infrastructure.
Pacific Biosciences Of California Inc Share Performance
+5.86%
One Year
Pacific Biosciences Of California Inc
Profile
Pacific Biosciences of California Inc's business model revolves around the development and commercialization of innovative sequencing systems that enable scientists and researchers to study the complexity of biology. They provide high-resolution genetic analysis solutions, offering a comprehensive platform that includes consumables, systems, and data analysis software to support genomic analysis.
Qiagen N.V. is a Dutch multinational company that operates in the field of molecular diagnostics and sample preparation technologies. Their business model revolves around developing and manufacturing products and solutions for molecular testing, enabling researchers and healthcare professionals to analyze biological samples and gain insights into diseases and genetic variations. Qiagen N.V. primarily generates revenue through the sale of instruments, consumables, and related services to customers in various market segments including academia, pharmaceuticals, and diagnostics.
Sources:
Twist Bioscience Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Twist Bioscience Corporation versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
